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CINTRODUCTION
Over 200 years ago, in 1796, Jenner introduced vacci-
nation, a name coined by Pasteur, as an effective means
to control one of the most devastating diseases of man-
kind, smallpox. Since then, a large number of vaccines
have been developed against many microbial pathogens
based on the use of live attenuated, heat-killed, or oth-
erwise inactivated microorganisms or their toxins (Plot-
kin, 1993). The main protective mechanisms elicited by
these vaccines are neutralizing antibodies. After multiple
doses of the same immunogen, the titers of antibodies
as well as their avidity increase, conferring maximal
protection. This strategy is used to induce large antibody
responses to intracellular pathogens such as viruses,
certain bacteria, fungi, and protozoans. Currently avail-
able vaccines, particularly those based on live attenu-
ated carriers, like poxvirus recombinants, can also in-
duce cell-mediated immunity which protects against cer-
tain viral diseases (Moss, 1996). However, the evaluation
of the magnitude, duration, and efficacy of the CD81 T
cell immune responses induced by these immunogens
has been difficult to ascertain in humans due to the
limited availability of appropriate, quantitative, antigen-
specific methods.
Recent advances in biotechnology have made it fea-
sible to identify and produce recombinant proteins ex-
pressing key microbial antigens/epitopes. This has been
particularly important in the case of pathogens that have
proven to be difficult if not impossible to grow in vitro.
The corresponding subunit vaccine candidates are being
produced as recombinant or synthetic polypeptides,
DNA, as well as recombinant bacterial or viral vectors
capable of inducing antibodies as well as T cell re-1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 34-91-585-4506. E-mail: mesteban@cnb.uam.es.
155sponses (Liljeqvist and Sthal, 1999). Unfortunately, how-
ever, relatively little is known regarding the most efficient
immunization strategy for activation and expansion of
effector and particularly memory T cells. Moreover, the
exact level of activated T cells required for full protection
against most infectious organisms remains to be deter-
mined. Resolving these questions will be important for
the development of new effective vaccines against a
variety of pathogens. These include vaccines for newly
emerging infections (HIV, Ebola, and hepatitis C), several
intracellular parasitic diseases such as malaria, leish-
maniasis, and trypanosomiasis, as well as certain ma-
lignancies.
Here we review the evidence that the effective booster
of T cell-mediated responses requires a different form of
antigen/epitope carrier than that used for priming and
that recombinant (re) poxviruses are excellent vectors
providing a most effective booster.
PRIMING OF SPECIFIC CD81 T CELL RESPONSES
BY SUBUNIT VACCINES
The recent realization that CD81 and also certain
D41 T cells play an important role in cell-mediated
protective immunity has stimulated intensive research to
identify the mechanisms involved in their activation, an
essential requisite to advance the rational development
of subunit vaccines. This finding has also given impetus
to the development of new methodologies to character-
ize and quantify the T cell responses to different immu-
nogens.
Many delivery systems have been investigated, such
as recombinant bacteria, viruses, naked DNA, RNA, as
well as various coated particles and synthetic peptides.
Overall, the relative ease with which primary CD81 T cell
responses can be elicited by immunization with each of
these immunogens has been established. However, a
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156 MINIREVIEWsignificant in vivo expansion of primary CD81 T cell
responses is difficult to achieve. Indeed, as shown in
different systems, the magnitude of CD81 T cell re-
ponses induced by a single immunizing dose of these
mmunogens peaks shortly after immunization and falls
hereafter, remaining detectable for several weeks and
ometimes even for months (Matloubian et al., 1994;
immerman et al., 1996; Murata et al., 1996). Once the
D81 T cell response is established, the number of
ntigen-specific T cells remains relatively stable; how-
ver, the number of antigen-specific T cells cannot be
ncreased in spite of repeated administration of the same
mmunogen (Murata et al., 1996).
The inability of the specific CD81 T cells induced in the
primary immune response to increase in number could
be due to the antagonistic effects exerted by other si-
multaneously elicited immune responses, such as neu-
tralizing antibodies and/or certain T cell subsets. These
might inhibit the infectivity of the vector and/or acceler-
ate its clearance by the reticuloendothelial system. How-
ever, failure to induce a significant secondary CD81 T
ell response also occurs after repeated immunization
ith MHC class I-restricted nonamer peptides (Miyahira
t al., 1998) and plasmid DNA (Schneider et al., 1998). In
hese cases, it appears unlikely that these vectors could
ave stimulated additional immune responses that could
ffect their capacity to induce secondary responses. An
ntriguing alternative explanation to this phenomenon
ould be found in an intrinsic inability of primed CD81 T
cells to divide during a prolonged period of time or to a
high mortality rate by apoptosis. Regardless of the mo-
lecular mechanism(s) which inhibits the expansion of in
vivo induced primary CD81 T cell responses, it has been
hown that this lack of expansion can be overcome by
sing an immunization strategy which combines different
e vectors expressing the same antigen or epitope (Li et
l., 1993; Rodrigues et al., 1994; Murata et al., 1996;
chneider et al., 1998; Sedegah et al., 1998; Robinson et
l., 1999; Ramshaw and Ramsay, 2000).
HIGHLY EFFICIENT SECONDARY T CELL
RESPONSE ELICITED BY RECOMBINANT
POXVIRUSES
The initial striking observation of the potent booster
ffect of recombinant vaccinia viruses was made by us in
993 (Li et al., 1993). The key finding was that priming
ice with recombinant influenza (reFlu) expressing a
D81 T cell epitope of the Plasmodium yoelii CS protein
followed by a booster with recombinant vaccinia viruses
(reVV) expressing the same epitope enhanced greatly
the specific CD81 T cell response. Mice immunized ac-
ording to this protocol displayed not only a strong sec-
ndary CS-specific CD81 T cell response—a 10- to 20-old increase in magnitude—but also, most importantly,
considerable degree of protection against malaria in-ection (Li et al., 1993; Rodrigues et al., 1994; Murata et
l., 1996). In sharp contrast, the reverse protocol, namely
riming with reVV followed by a booster with reFlu, failed
o elicit a strong secondary T cell response or protection
gainst malaria challenge. Similar results were obtained
n mice immunized with irradiated P. yoelii or Plasmo-
ium falciparum sporozoites in which the CD81 T cell
esponse could not be enhanced by repeated exposure
o these parasites. Moreover, it was found that parasite-
nduced CS-specific CD81 T cell responses could be
ncreased 10- to 20-fold after booster with a reVV ex-
ressing the CS epitope (Miyahira et al., 1998). These
esults clearly demonstrate that reVV is essential for the
nduction of the large booster effect.
In recent studies using the P. yoelii malaria model, it
as shown that priming with recombinant virus-like par-
icles (VLPs) derived from a yeast retrotransposon
TyVLPs), carrying the P. yoelii CS CTL epitope, followed
y boosting with a reVV expressing the CS protein,
nduced strong secondary CD81 T cell responses that
protected 62% of mice against sporozoite challenge (Ol-
iveira-Ferreira et al., 2000). This is important since re-
combinant VLPs containing HIV antigens have already
been tested in clinical trials in humans with no adverse
reactions (Weber et al., 1995; Peter et al., 1997).
In studies in which the immunogenicity of different
viral vectors expressing the CD81 T cell epitope of the P.
oelii CS protein was compared, it was found that each
f these viral vectors, i.e., Sindbis, Adeno, influenza, and
accinia viruses, induced a considerable CS-specific
D81 primary response (Murata et al., 1996; Rodrigues
t al., 1997; Tsuji et al., 1998). However, the in vivo
xpansion of an established CD81 T cell response was
ifficult to achieve unless a specific combination of im-
unogens were used as primers and boosters. The fact
hat other recombinant viruses (Murata et al., 1996), DNA
Schneider et al., 1998), synthetic peptides (Miyahira et
l., 1998), and virus-like particles (Oliveira-Ferreira et al.,
000) are incapable or rather inefficient at inducing large
econdary CD81 T cell responses suggests the exis-
tence of severe constraints for the in vivo expansion of
memory T cells. Importantly, these studies indicated that
recombinant vaccinia virus is the vector that most effi-
ciently boosts memory CD81 T cell responses.
The enhancement provided by re vaccinia virus is not
restricted to malaria antigens since enhancement also
occurred in mice primed with influenza virus and
boosted with a reVV expressing the influenza nucleopro-
tein (NP). The combined immunization also resulted in a
greatly enhanced secondary anti-NP-specific CD81 T
cell response (Murata et al., 1996). An equally enhanced
T cell response was observed upon immunization with
the V3 CTL epitope of the envelope (env) protein of the
HIV-1 virus, expressed by reFlu, followed by a booster
with reVV expressing the entire env protein (Gonzalo et
al., 1999).
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157MINIREVIEWBOOSTER EFFECT OF ATTENUATED AND
REPLICATION-DEFICIENT POXVIRUSES
In areas where there is a high prevalence of HIV-
induced immunosuppression, vaccine safety is particu-
larly important. Therefore, there has been particular em-
phasis on developing nonpathogenic antigen delivery
systems capable of inducing effective CD81 T cell re-
sponses. Synthetic peptides modified by the addition of
lipid moieties and recombinant VLPs, and possibly also
naked DNA, fulfill these requirements as safe vaccines
for human use. Although the T cell response to priming
with each of these immunogens is relatively low, it can
be greatly enhanced when reVV expressing the corre-
sponding antigen was used for booster.
Importantly, we and others observed that the booster
effect of reVV is not dependent on its infectivity, since
strong secondary T cell responses and protection
against malaria can be elicited by attenuated reVV. In
these studies, priming of mice with reFlu virus followed
by boosting with the replication-deficient vaccinia virus
mutant M7.PYCS (Rodrigues et al., 1994) or priming with
a plasmid DNA followed by boosting with the attenuated
modified vaccinia virus Ankara strain (Schneider et al.
1998) induced higher numbers of specific CD81-specific
T cells and a higher degree of protection than repeated
immunization with the same vector.
A most promising attenuated vaccinia strain is the
modified vaccinia virus Ankara (MVA), a deletion mutant
which resulted from serial passages of the parental VV
Ankara strain in chick embryo fibroblast CEF cells, a
process during which the virus lost the capability to
replicate in mammalian hosts (Mayr et al., 1978; Meyer et
al., 1991; Sutter and Moss, 1992). Since MVA has been
tested in humans during the smallpox vaccination cam-
paign and proved to be safe, this viral strain has become
the vector of choice for booster of vaccine candidates.
Specific characteristics of the MVA vector, such as lack
of expression of several immunomodulatory proteins and
induction of type I IFN (Blanchard et al., 1998), may
explain the greater immunogenicity of recombinant vi-
ruses based on MVA. This has also been noticed in other
studies with MVA recombinants expressing simian im-
munodeficiency virus (SIV) and influenza antigens (Sutter
et al., 1994; Moss et al., 1996).
The work by Degano et al. (1999) has shown that in the
prime/boost regime, large CD81 T cell responses and
evels of protection were achieved when using DNA
elivered by intramuscular injection or a gene gun fol-
owed days after by iv administration of reMVA. Further-
ore, the simultaneous enhancement of the CD81 T cell
response against two epitopes from different pathogens,
HIV and Plasmodium, has been achieved in mice by the
DNA/reMVA prime/boost regime, using DNA and MVA
vectors, both expressing a multiepitope polypeptide
(Hanke et al., 1998).In another study, it was shown that recombinant VLPs
derived from a yeast retrotransposon (TyVLPs), contain-
ing the CTL epitope of the Plasmodium berghei CS pro-
tein, was found to induce specific antimalaria CTLs (All-
sop et al., 1996). Combined immunization with TyVLPs
followed by the administration of reMVA expressing the
P. berghei CS protein CTL epitope provided 95% protec-
tion against malaria in mice (Gilbert et al., 1997; Pleban-
ski et al., 1998; Schneider et al., 1999).
An important finding was that the efficiency of the
combined prime/boost approach to induce high levels of
CD81 cells is not restricted to murine models. The prime/
boost regime using a nonreplicating poxvirus to boost
the immune response elicited by a different vector has
also been successfully applied in macaques. Immuniza-
tion of macaques (Macaca nemestrina) by priming with
DNA and boosting with a recombinant fowlpox (reFPV),
both encoding HIV-1 env, gag, and pol antigens, was
found to generate a marked enhancement of HIV-1-
specific CTL and Th responses and protection against a
nonpathogenic HIV-1 challenge (Kent et al., 1998). Nei-
ther of these two vectors was by itself able to generate a
consistent CTL response. In another study in rhesus
monkeys, using several immunization protocols, a T cell-
mediated protective immune response against chimeras
between simian and human immunodeficiency viruses
was only obtained by priming with DNA followed by
boost with reFPV (Robinson et al., 1999). Further demon-
stration of the efficacy of the heterologous prime/boost
approach in macaques was provided by Hanke et al.
(1999), demonstrating that high levels of CD81 T cells
pecific for the gag protein from SIV were induced in
hesus macaques by sequential immunization with plas-
id DNA and a reMVA.
The immunological mechanisms of the booster effect
f reVV on the expansion of CD81 T cells are not yet
known. It is currently accepted that during priming with a
variety of vectors (i.e., DNA, VLPs, live virus), there is a
moderate activation of CD81 T cells triggered by a few
pitopes and that after booster with reVV expressing the
ame antigen there is expansion of the specific CD81 T
ell population in addition to the priming effect on naive
mmune T cells. The prime antigen-specific memory cells
an react faster and expand more rapidly. The potent
D81 T cell expansion effect of reVV might also be
related to virus-induced activation of immunomodulators.
Indeed, VV infection of animals can trigger the induction
of some cytokines (Gherardi et al., 1999). Considering
that poxviruses encode a large number of proteins that
control the host immune responses such as comple-
ment, interferons, other cytokines, and chemokines (Al-
cami and Koszinowski, 2000), it is likely that many of
these soluble inhibitors influence the extent of immune
responses. Significantly, MVA does not encode many of
the soluble cytokine receptors, like IFN-a/b, IFN-g, TNF,
or the virus chemokine binding protein. Future studies
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158 MINIREVIEWshould aim at modulating the poxvirus vector immuno-
genicity by the selective inactivation of viral inhibitors on
immune functions and/or by the incorporation in the
vector genome of selected cytokines. In this way, we
might be able to further enhance and modulate the spe-
cific CD81 T cell responses to selected antigens induced
y recombinant poxvirus vectors.
In conclusion, these studies demonstrate that there
re relatively few restrictions for the induction of primary
pecific CD81 T cell responses by immunization with
different vectors. However, a significant expansion of
these cells during secondary T cell responses only oc-
curs under very restricted conditions of immunization.
Such an expansion is most efficiently accomplished by
using re poxviruses expressing the same foreign anti-
gen/epitope. The promise of the prime/boost immuniza-
tion approach is highlighted by several human vaccine
trials against malaria, HIV, and melanoma, currently ap-
proved or in the planning stage, all based on prime/boost
immunization using recombinant poxvirus vectors. We
hope that this or a related approach, and the correspond-
ing findings, will provide the basis for the design of new,
safe, and effective vaccines against various pathogens
which still cause severe human diseases.
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